Imunon公司（纳斯达克股票代码：IMNN）今日公布了其候选疗法IMNN-001的最新临床研究数据。结果显示，与对照组相比，接受IMNN-001治疗的患者群体在多项关键疗效指标上均展现出显著优势。
具体而言，该疗法在降低微小残留病灶（MRD）率方面表现突出。这意味着治疗后体内残留的癌细胞数量更少，疾病复发风险可能随之降低。
同时，研究数据表明，IMNN-001组患者表现出更高的循环肿瘤DNA（ctDNA）清除率。ctDNA的清除是评估治疗效果和监测疾病状态的重要分子标志，其高清除率通常预示着更好的治疗应答。
此外，与对照组相比，IMNN-001治疗组的无病生存（NED）率也更高。这一结果进一步支持了该疗法在延长患者无疾病生存期方面的潜在价值。
这些积极的初步数据为IMNN-001的后续临床开发提供了有力支持，并可能为相关癌症患者带来新的治疗希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.